Summary
The pharmacokinetics of chlormethiazole after oral and intravenous administration was studied in six healthy volunteers and eight patients with alcoholic cirrhosis of the liver. Plasma concentration-time curve after the intravenous infusion could adequately be described by two- or three-compartment open models both in healthy volunteers and in the patients. Based on the areas under the plasma concentration-time curves, the systemic bioavailability of oral chlormethiazole was about ten times greater in the patients than in healthy controls. The elimination of chlormethiazole was relatively less retarded in the patients, as indicated by a decrease of about 30% in its plasma clearance. In the patients the plasma protein binding of chlormethiazole was decreased, but the volume of distribution and half-life of elimination were unchanged. The increase in bioavailability of chlormethiazole was associated with significant alteration in the serum levels of bilirubin, albumin, alkaline phosphatase, prothrombin-proconvertin activity (P + P) and elimination rate of antipyrine or14C-aminopyrine. The increased bioavailability of oral chlormethiazole was due to impaired first-pass metabolism in the cirrhotic liver. A considerable reduction in dose seems to be indicated if oral chlormethiazole is used in patients with advanced cirrhosis of the liver. A substantial fraction of dose, averaging 15%, was lost during the intravenous infusion, presumably due to adsorption to the infusion tubing.
Similar content being viewed by others
References
Boxembaum HG, Riegelman S, Elashoff RM (1974) Statistical estimations in pharmacokinetics. J Pharmacokinet Biopharm 2: 123–148
Branch RA, Shand DG (1976) Propranolol disposition in chronic liver disease: A physiological approach. Clin Pharmacokinet 1: 264–279
Ehrnebo M, Agurell S, Boréus LE, Gordon E, Lönroth U (1974) Pentazocine binding to blood cells and plasma proteins. Clin Pharmacol Therap 16: 426–429
Frisch EP (ed) (1966) Chlormethiazole (Heminevirin, Distraneurin). Proceedings of a Symposium. Munksgaard, Copenhagen, p 233
Gibaldi M, Nagashima R, Levy G (1969) Relationship between drug concentration in plasma or serum and amount of drug in the body. J Pharm Sci 58: 193–197
Gross G, Perrier CV (1975) Intrahepatic portasystemic shunting in cirrhotic patients. N Engl J Med 293: 1046–1047
Groszmann R, Kotelanski B, Cohn JN, Khatri IM (1972) Quantitation of portasystemic shunting from the splenic and mesenteric beds in alcoholic liver disease. Am J Med 53: 715–722
Hepner GW, Vesell ES (1974) Assessment of aminopyrine metabolism in man by breath analysis after oral administration of14C-aminopyrine. Effects of phenobarbital, disulfiram and portal cirrhosis. N Engl J Med 291: 1384–1388
Horder JM (1978) Fatal chlormethiazole poisoning in chronic alcoholics. Br Med J 1: 693–694
Hossfeld D (1969) Todesfällel bei Alkoholdelir unter Distraneurin-Medikation. Med Welt 33: 1806–1808
Jakobsson SV, Möller M (1972) Deaths due to chlormethiazole Heminevrin®, Hemineurine®, Distraneurin® (Abstract), Sixth International Meeting Forensic Science, Edinburgh September
Jostell KG, Agurell S, Allgén L-G, Kuylenstierna B, Lindgren J-E, Åberg G, Österlöf G (1978a) Pharmacokinetics of chlormethiazole in healthy adults. Acta Pharmacol Toxicol 43: 180–189
Jostell KG, Agurell Sl, Hollister LE, Wermuth B (1978b) Kinetics of chlormethiazole in patients with alcohol with-drawal manifestations. Clin Pharmacol Ther 23: 181–187
Loo TL, Tanner BB, Housholder GE, Shepard BJ (1968) Some pharmacokinetic aspects of 5-(dimethyltriazerin)-imidazole-4-carboxamide in the dog. J Pharm Sci 57: 2126–2131
Loo JCK, Riegelman S (1970) Assessment of pharmacokinetic constant from postinfusion blood curves obtained after I V infusion. J Pharm Sci 59: 53–55
Mawer GE, Miller NE, Turnberg LA (1972) Metabolism of amylobarbitone in patients with chronic liver disease. Br J Pharmacol 44: 549–560
Metzler CM, Elfring GL, McEven AJ (1974) A package of computer programs for pharmacokinetic modeling. Biometrics 30: 562–563
Moore RG, Triggs EJ, Shanks CA, Thomas J (1975) Pharmacokinetics of chlormethiazole in humans. Eur J Clin Pharmacol 8: 353–357
Nation RL, Learoyd B, Barber J, Triggs EJ (1976) The pharmacokinetics of chlormethiazole following intravenous administration in the aged. Eur J Clin Pharmacol 10: 407–415
Nation RL, Vine J, Triggs EJ, Learoyd B (1977) Plasma level of chlormethiazole and two metabolites after oral administration to young and aged human subjects. Eur J Clin Pharmacol 12: 137–145
Pentikäinen PJ, Valtonen VV, Miettinen TA (1976) Deaths in connection with chlormethiazole (Heminevrin®) therapy. Int J Clin Pharmacol 14: 225–230
Pentikäinen PJ, Neuvonen PJ, Tarpila S, Syvälahti E (1978) Effect of cirrhosis of the liver on the pharmacokinetics of chlormethiazole. Br Med J 2: 861–863
Perrier D, Gibaldi M (1973) Relationship between plasma or serum drug concentration and amount of drug in the body at steady state upon multiple dosing. J Pharmacokinet Biopharm 1: 17–22
Perrier D, Gibaldi M (1974) Clearance and biologic half-life as indices of intrinsic hepatic metabolism. J Pharmacol Exp Ther 191: 17–24
Pessayre D, Lebrec D, Descatoire V, Peignoux M, Benhamou J-P (1978) Mechanism for reduced drug clearance in patients with cirrhosis. Gastroenterology 74: 566–571
Prescott LF, Adjepon-Yamoah KK, Roberts E (1973) Rapid gas-liquid chromatography estimation of antipyrine in plasma. J Pharm Pharmacol 25: 205–207
Wilkinson GR, Shand DG (1975) A physiological approach to hepatic drug clearance. Clin Pharmacol Ther 18: 377–390
Wilkinson GR, Schenker S (1975) Drug disposition and liver disease. Drug Metab Rev 4: 139–175
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pentikäinen, P.J., Neuvonen, P.J. & Jostell, K.G. Pharmacokinetics of chlormethiazole in healthy volunteers and patients with cirrhosis of the liver. Eur J Clin Pharmacol 17, 275–284 (1980). https://doi.org/10.1007/BF00625801
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00625801